Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
This article was originally published in The Gray Sheet
Executive Summary
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum